You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Baxter
McKinsey
Mallinckrodt

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Fotemustine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Fotemustine?

Fotemustine is an investigational drug.

There have been 16 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.

The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.

There are two US patents protecting this investigational drug and thirty-one international patents.

Recent Clinical Trials for Fotemustine
TitleSponsorPhase
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaMingzhi ZhangPhase 4
A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGenenta SciencePhase 1/Phase 2
MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma PatientsAzienda Sanitaria di FirenzePhase 2/Phase 3

See all Fotemustine clinical trials

Clinical Trial Summary for Fotemustine

Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine

See all Fotemustine clinical trials

US Patents for Fotemustine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fotemustine   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Fotemustine   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Fotemustine   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Fotemustine   Start Trial Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fotemustine

Drugname Country Document Number Estimated Expiration Related US Patent
Fotemustine World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Fotemustine Australia 2015231053 2034-03-21   Start Trial
Fotemustine Brazil 112016021620 2034-03-21   Start Trial
Fotemustine Canada 2943339 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.